Navigation Links
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
Date:3/29/2009

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are prospective, randomized, non-inferiority trials with 300 and 1,002 patients respectively, designed to compare the safety and efficacy of the PROMUS(R) (XIENCE V(TM)) Everolimus-Eluting Coronary Stent to Boston Scientific's first-generation TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent. SPIRIT II three-year results were presented by Patrick W. Serruys, M.D., Ph.D, and the two-year meta-analysis was presented by Yoshinobu Onuma, M.D., at the 58th Annual Scientific Session of the American College of Cardiology.

The two-year pooled meta-analysis was intended to estimate the incidence of low frequency events or outcomes in key subgroups, and included 892 patients randomized to the PROMUS (XIENCE V) Stent and 410 patients treated with the TAXUS Stent. While overall pooled results and some subgroups at two years favored the PROMUS (XIENCE V) Stent for rates of Major Adverse Cardiac Events (MACE), the MACE results in patients with diabetes favored the TAXUS Stent.

"Clinical data presented at ACC continue to reinforce the value of Boston Scientific's two-drug portfolio," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "While the PROMUS (XIENCE V) Stent performed well against the TAXUS Stent in the meta-analysis, it is important to note that 96 percent of the control patients received the TAXUS Express Stent, making the comparison almost entirely based on our first-generation technology. Of particular interest is the subgroup data on diabetics given the recent discussion in scientific journal
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
3. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
4. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
5. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
6. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
7. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. Another LNA-based RNA Inhibitor Enters Clinical Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009).../ -- Reportlinker.com announces that a new market ..., Inflammatory Disorders: Therapies That Suppres...w.reportlinker.com/p0165600/Inflammatory-Disorders...ponse.html ,, The human immune system can go a...ing an exaggerated response to a foreign substance...
(Date:11/30/2009)... Jocelyn Rapelyea, Associate Director of Breast Im...sity Medical Center in Washington, D.C., demonstra...ific Gamma Imaging (BSGI) can be localized utilizi...l, as for pre-operative localization today at the ...h America (RSNA). ,, BSGI was conducted using a...
(Date:11/30/2009)...- Minimally-invasive procedures are increasingly r... oncology, cardiology and women,s health applicati...tion expected to reach $600 million by 2015, clini...mally-invasive procedures, including shorter patie...ter patient throughput. ,, (Logo: http://www...
Breaking Medicine Technology:Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5Lexington Health Care Names New Chief Executive Officer 51899 1Lexington Health Care Names New Chief Executive Officer 51899 2Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 1Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 2Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 3Technology Collaborative Launches Online Game to Exercise Brain Power of People with Multiple Sclerosis 51897 4PAL Health Technologies Wins State Level Prestigious Employer of the Year Award 51895 1PAL Health Technologies Wins State Level Prestigious Employer of the Year Award 51895 2
...ults of Roche and Ipsen,s First Once-Weekly Human ...iation Meeting -, NUTLEY, N.J., June 10 Roche an...poglutide (R1583) has been shown to provide,signif...oss after only,eight weeks of treatment(1,2) with ...try into Phase III. Taspoglutide, originating from...
...estigational Diabetes Therapy Also Improved Glucos... Taken Twice a Day, SAN FRANCISCO, June 9 Amylin...and Company (NYSE: LLY ), and Alkermes, Inc.,(Nas...k open-label clinical,study that showed the durabl... release formulation of exenatide. Patients taking...
Other Medicine Technology:Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 2Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 3Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 4Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 5Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9
(Date:11/30/2009)...NEW ORLEANS, Nov. 30 SE... the global corporation Sodexo will hold a rally T... and Maintenance headquarters, 3800 Desire Parkway...licy and arbitrary disciplinary policies that targ...n ill family member. Sodexo employees who clean sc...
(Date:11/30/2009)...HARLTON, Mass., Nov. 30 Harrington...he addition of Family Practice physicians Martin D...hur to its Charlton practice. ,, These four e...ing from the Fallon Clinic, will soon join the Har... Charlton medical office building under constructi...
(Date:11/30/2009)... tiny period of time between the registration of a...onscious recognition of it ― between the tim...an apple. Our minds lag behind our eyes, but by ho...the world around us? , Some estimates say the ... 500 milliseconds. A new study by Tel Aviv Univers...
(Date:11/30/2009)...cial skills improve with specially designed progra...thDay News) -- A special, intensive early interven... boosting IQ along with children,s language and so... this fashion, many children are able to learn and... lead author of the study, published online Nov. 3...
(Date:11/30/2009)... , SILVER SPRING, Md., Nov. 30 /PRNewswire-USN...umers a bronzed body year-round, but the ultraviol... health risks. ,, (Logo: http://www.newscom.c...h some people think that a tan gives them a ,healt...Sharon Miller, M.S.E.E., a Food and Drug Administr...
Breaking Medicine News(10 mins):Health News:As H1NI Hits New Orleans in Force: School Custodians to Hold Rally to Call on Contractor to Stop Penalizing Workers Coping With Illness 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3Health News:Now you see it, now you know you see it 2Health News:Working Intensely Early on May Help Autistic Kids 2Health News:Working Intensely Early on May Help Autistic Kids 3Health News:Working Intensely Early on May Help Autistic Kids 4
... health conditions are potentially around the corn...tudy. The findings, which were based on analys...cells, appear online March 6 in the American Journ... M.D., Ph.D., professor of psychiatry in the UI Ro...
...ty goers at night clubs has prompted authorities t...ners to refrain from such acts, lest they risk fac... Medicines and Healthcare Products Regulatory Agen...uncils have been asked to warn the clubs, festival...
... a method that could lead to a single vaccine agai...e dengue virus causes dengue hemorrhagic fever, sh...all sufficiently different that individuals vaccin... against all types of dengue virus. But John...
...ts of a study showing clearly that soft drinks are...r body weight, a decrease in calcium and other nut... The report also noted that studies funded by t...analyzed 88 previously published studies obtained ...
...ain reliever for children suffering severe musculo...and codeine. Details of the study are published in... Nearly 336 children aged from 6 to 17 sought tre...he children were randomly administered oral doses ...
...rt treatment for morbidly obese adults with accomp...rformed in teens. As statistics from research... New Jersey show, the use of surgery to treat obes...a year in which 771 of these operations were perfo...
Other Medicine News:Health News:Blood Tests may Be Possible for Mental Health Conditions 2Health News:Yale Researchers Weigh the Science on Soft Drinks and Health 2Health News:Extreme Treatment for Obese Teens Becoming a Fad 2
Laser Contact Lens Retina 145 L
Laser 3 mirror Contact Lens 907 L
Laser 3 mirror Contact Lens 630 L
...mplete image capture and management application th...l leading ophthalmic clinicians, ophthalmic photog...urately and securely document the eye via the slit...slit lamps equipped with digital or video cameras ...
Medicine Products: